View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Steven Gould
  • Steven Gould
Steven Gould
  • Steven Gould
Stefano Toffano ... (+2)
  • Stefano Toffano
  • Wim Gille
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Belgian telcos: Telenet small positive net adds, good financials, guidance up. Kinepolis: US Cinemark strong, 5% growth in US tickets, consumption per visitor. KPN: VodafoneZiggo 2Q25 very weak, guidance maintained. PostNL: 2Q25 beats underlying slightly; FY25 guidance reiterated, EU court appeal

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Livio Luyten
  • Michiel Declercq
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

argenx 1H25 conference call feedback

argenx reported 1H25 results today, with Vyvgart sales showing a solid CSS beat. In this note you can find our main takeaways from the conference call. ARGX-119 phase 3 in CMS - argenx emphasized that they currently have 3 assets in phase 3 development with the advancement of ARGX-119 to phase 3 in Congenital Myasthenic Syndrome (CMS). ARGX-119 targets MuSK in the neuromuscular junction and is advanced in CMS, an ultra-rare disease. This allows for a small trial with dense monitoring of patients...

Louis Boujard ... (+4)
  • Louis Boujard
  • CFA
  • Philippe Ourpatian
  • Thomas Zlowodzki
Louis Boujard ... (+3)
  • Louis Boujard
  • CFA
  • Philippe Ourpatian
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
Jacob Mekhael
  • Jacob Mekhael

argenx Vyvgart 2Q25 sales show solid CSS beat

argenx reported another strong quarter with Vyvgart sales coming in at $ 949m, beating CSS by approx. 10%. argenx reached operating profitability for the 4th consecutive quarter, and is on track for FY25 profitability. Pipeline timelines are reiterated and we look ahead to the upcoming readouts in seronegative gMG (2H25), as well as PoC results in lupus nephritis (Vyvgart, 4Q25) and delayed graft function (empa, 2H25). ARGX-119 R&D day set for 16 September. Accumulate/ € 670 TP reiterated.

Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, ARGX BB, BEKB BB, CRBN NA, DSFIR NA, ENX FP, F...

: ABI BB, ARGX BB, BEKB BB, CRBN NA, DSFIR NA, ENX FP, FAGR BB, FLOW NA, INGA NA, ONTEX BB, UCB BB, AZE BB, SYENS BB

 PRESS RELEASE

argenx Reports Half Year 2025 Financial Results and Provides Second Qu...

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update $949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional topline data readouts across pipeline remain on track for second half of 2025 Management to host conference call today at 2:30 PM CET (8:30 AM ET) July 31, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a gl...

Pierre FerraguÊ ... (+2)
  • Pierre FerraguÊ
  • Rolf Bulk

Besi 2Q25 QT: Hybrid bonding inflection to drive 2H orders; mainstream...

Besi reported 2Q25 this morning. Please click the link below for our quick take on the print.

 PRESS RELEASE

argenx to Report Half Year 2025 Financial Results and Second Quarter B...

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025 July 24, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ASM: 2Q25 Preview, AI winner BE Semiconductor Industries: 2Q25 Preview, focus on advanced order intake CM.com: Preview 1H25 D'Ieteren: Belron $4.655bn TBL repriced 25bp lower PostNL: Preview 2Q25F; consensus released Wolters Kluwer: To divest Finance, Risk and Regulatory Reporting unit

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Kinepolis: Cineplex June 2025 box office rev at 91% of 2019, outperforming N America. TomTom: Preview 2Q25 - restructuring impact. Vopak: JV with IHI to start up ammonia by 2030

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

CM.com: Departure of CFO Jörg de Graaf. PostNL: Highlights of 2Q25 pre-earnings analyst call. Shell plc: 2Q25 a touch better than earlier indicated

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Kinepolis: June 2025 Box office revenue/ attendance in US/Canada and France down. Utilities – Offshore Wind: Big Not So Beautiful Bill

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update July: Removing Fagron and Melexis, Adding...

Since the last publication of our Dynamic Top Pick List on 5 June 2025, our selection has seen again a nice outperformance versus the reverence indices (AEX, Bel20 and Eurostoxx50) of on average 3.3%. Our July update brings 3 adjustments to the list : Since being added to the list in December 2024, Fagron's share price has surged +/-22%, driven by strong Q1 2025 results and robust growth across all regions. Fagron reaffirmed its FY25 guidance and unveiled its “Compounding for Growth” strategy, ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch